about
Pharmacogenetics and pharmacogenomics as tools in cancer therapyIntegration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme.Alteration in endoglin-related angiogenesis in refractory cytopenia with multilineage dysplasiaDown-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemiaAn international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase.MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme.Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.Fluorescencein situhybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemiaCorrelation of myelodysplastic syndromes with i(17)(q10) andTP53andSETBP1mutationsImatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progressionChromosomal abnormalities are related to location and grade of osteoarthritisAnalysis of chromosomal imbalances in an elderly woman with a giant cell tumourThe presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab
P50
Q28076200-672F0F9B-1F20-4A2A-AD63-7BCF223CD4D8Q34259262-3125BD43-280C-4A01-AFED-5F4817362B2EQ34558522-36FF6A68-D448-465D-A456-44AB7393D0E0Q35265855-B799F412-6F7A-4031-8378-B605F84CD6D8Q37125395-D41C79C0-C07B-4845-B08C-EA277D8CABF8Q40783027-7F0F28BC-9353-48E3-AE06-55D570566DBBQ45155324-97D2E6F6-E0B2-4BCF-A58B-30BAD874F69DQ45904545-668AD686-6E27-4B50-9485-206E7E7AE4A1Q46415118-41BF3E74-5294-4105-A1F1-D7613AE3C1A9Q47238301-F8087A6E-3A80-4D8A-BFFE-611FAB1D0CD4Q48419123-1D52AA83-2D80-4E64-9566-CB7672451827Q53101662-16070AD3-AD4E-4D86-BCDF-351318B39AFAQ53469016-E9C50239-8758-474C-8D2D-65F4EE51DAB6Q58010065-75844B15-EEDB-4246-85A7-30CCB75E09B7Q58074618-972BA527-B556-4177-953C-49633E80BFA7Q60203506-3BA37060-94DC-4BC2-A947-A1F90FE9E24EQ60203939-76098CDE-BAA8-424A-9EC3-4D478B27106CQ81342012-2D1CF33E-E3CB-459B-8F40-44EC7A519B8BQ86699332-EABDAF98-93D2-4903-BFA7-5D554295EF60
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eva Lumbreras
@ast
Eva Lumbreras
@en
Eva Lumbreras
@es
Eva Lumbreras
@nl
Eva Lumbreras
@sl
type
label
Eva Lumbreras
@ast
Eva Lumbreras
@en
Eva Lumbreras
@es
Eva Lumbreras
@nl
Eva Lumbreras
@sl
prefLabel
Eva Lumbreras
@ast
Eva Lumbreras
@en
Eva Lumbreras
@es
Eva Lumbreras
@nl
Eva Lumbreras
@sl
P106
P21
P31
P496
0000-0003-0359-6199